Bexion Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, announced yesterday that it has named Bob Savage, MBA as its director.

Savage brings to the Bexion Board more than 40 years of experience in marketing, sales, drug development, operation and business development in the pharmaceuticals and biotechnological industries. His areas of expertise include clinical development, go-to-market strategy, regulatory affairs, manufacturing, quality assurance, sales, marketing, talent management, executive coaching, business development, M & A and P & L management. He has held leadership positions with organisations including Pharmacia Corporation, Johnson & Johnson, and Hoffmann La-Roche. As group VP and president of the Worldwide General Therapeutics & Inflammation Business with Pharmacia Corporation, he held global responsibility for a portfolio with an annual net income of over USD5bn. In the role of worldwide chairman, Pharmaceuticals Group with Johnson & Johnson, Savage oversaw a business unit with over USD11bn in annual sales and 43,000 employees. As an experienced board member, he has been a Director with over a dozen organisations including Humanigen, Depomed, The Medicines Company, Medworth Acquisition Corporation, Savient Pharmaceuticals, Panacos Pharmaceuticals, Epicept Corporation, Noven Pharmaceuticals, Vela Pharmaceuticals, The Neurological Institute of New Jersey, The Epilepsy Foundation of America, and Robert Wood Johnson Medical School.

Chuck Scheper, Bexion board chairman, said, 'We are very excited to have someone with Bob's depth of pharmaceutical knowledge join the Bexion Board of Directors. His breadth of experience will contribute to Bexion's ongoing success as we progress with our clinical development plan.'